Literature DB >> 2414458

Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

J C Wright.   

Abstract

An update in cancer chemotherapy that deals with the various therapies of lung cancer is described. At present, the stage of the disease and cell type are the major factors that determine the treatment. Important differences in the biological behavior and response to treatment exist between small cell and non-small cell cancers. The small cell type is sensitive to many chemotherapeutic agents. Differences in response to chemotherapy and survival have been less among the non-small cell types.The treatment of non-small cell carcinomas including squamous cell, large cell, and adenocarcinoma are reviewed in Part I of this paper. Small cell lung cancer will be described in Part II, which will be published in a future issue of the journal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2414458      PMCID: PMC2571176     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  53 in total

1.  MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.

Authors:  A P Chahinian; E M Mandel; J F Holland; I S Jaffrey; A S Teirstein
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

2.  Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung.

Authors:  R T Eagan; S Frytak; E T Creagan; J N Ingle; L K Kvols; D T Coles
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

3.  MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung: low response rate in a Cooperative Group Study. Eastern Cooperative Oncology Group.

Authors:  S E Vogl; C R Mehta; M H Cohen
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

4.  VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

Authors:  R T Eagan; J N Ingle; E T Creagan; S Frytak; L K Kvols; J Rubin; R T McMachon
Journal:  Cancer Treat Rep       Date:  1978-05

5.  Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung.

Authors:  R J Gralla; B G Raphael; R B Golbey; C W Young
Journal:  Cancer Treat Rep       Date:  1979-08

6.  Regional immunotherapy of lung cancer with intrapleural B.C.G.

Authors:  M F McKneally; C Maver; H W Kausel
Journal:  Lancet       Date:  1976-02-21       Impact factor: 79.321

7.  cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung.

Authors:  R J Gralla; E Cvitkovic; R B Golbey
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

8.  5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung.

Authors:  T P Butler; J S MacDonald; F P Smith; L F Smith; P V Woolley; P S Schein
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

9.  cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung.

Authors:  J C Britell; R T Eagan; J N Ingle; E T Creagen; J Rubin; S Frytak
Journal:  Cancer Treat Rep       Date:  1978-08

10.  Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung: a Southwest Oncology Group Study.

Authors:  R B Livingston; L Helibrun; D Lehane; J J Costanzi; R Bottomley; R L Palmer; W J Stuckey; B Hoogstraten
Journal:  Cancer Treat Rep       Date:  1977-12
View more
  1 in total

1.  Inhibition of Calcium-Activated Chloride Channel ANO1/TMEM16A Suppresses Tumor Growth and Invasion in Human Lung Cancer.

Authors:  Linghan Jia; Wen Liu; Lizhao Guan; Min Lu; KeWei Wang
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.